News & analysis on the clinical development and manufacture of large molecule drugs
Cytovance Biologics, Yuk Chun Chiu
By Ben Hargreaves
- Last updated on
Cytovance Biologics, a contract development and manufacturing organization focused on biologic active pharmaceutical ingredients (APIs), announced the appointment of Yuk Chun Chiu as its VP of manufacturing operations.
Chiu was brought onto the team by Cytovance’s newly appointed CEO, Jesse McCool, after the pair previously worked together at Lonza, where McCool held the role of director of process development, immediately prior to joining Cytovance.
Chiu will be responsible for directing manufacturing operations, managing the supply chain, engineering and facilities for the CDMO.
While McCool suggested that Chiu’s previous experience managing commercial manufacturing will be ‘critical’ to advancing Cytovance’s late-stage pipeline of recombinant proteins and gene therapies.
Chiu’s former roles include working as director of manufacturing and engineering at AstraZeneca, and also as group head of process analytical technology with Bayer.